Tumour vaccines

A tumour vaccine is an agent used for cancer therapy or cancer prevention that elicits an immune response and induces protective immunity against specific molecules (antigens) expressed on tumour cells. There are currently no vaccines that can prevent cancer from developing, but some therapeutic tumour vaccines have shown promise in patients with selected cancers.

Latest Research and Reviews

News and Comment

  • News & Views |

    Cancer vaccines can elicit tumor-specific T cells, but sustaining their function via immune checkpoint therapy (ICT) may be required for robust anti-tumor immunity. A new study reveals that neoantigen cancer vaccines synergize with anti-PD-L1 ICT in a preclinical model and provides mechanistic insights into this synergy.

    • Alexander S. Shavkunov
    •  & Matthew M. Gubin
    Nature Cancer 3, 376-378
  • Comments & Opinion |

    mRNA vaccines have proven safe and effective in preventing serious illness and death during the COVID-19 pandemic. In this Comment, Morris and Kopetz argue that these technologies offer a novel approach towards personalizing immune-based treatments for patients with cancer with the potential for immune activation beyond commonly utilized immunotherapies.

    • Van K. Morris
    •  & Scott Kopetz
    Nature Reviews Cancer 22, 317-318
  • Research Highlights |

    Guo et al. have developed a novel strategy, which involves coating tumour cells with silica, to enable personalized cancer vaccines to overcome the immunosuppressive effects of the tumour microenvironment.

    • Anna Dart
  • News & Views |

    Tumour-associated antigens are an attractive therapeutic target in immuno-oncology. Here, the exploratory analyses of T cell responses and preliminary clinical outcomes of the Lipo-MERIT trial of a melanoma vaccine are discussed in the context of prior efforts to harness the immunogenicity of such antigens for antitumour immunity.

    • Anjali Rohatgi
    •  & John M. Kirkwood
  • News & Views |

    The fusion of an immunogenic peptide and the protein transthyretin protects the peptide antigen from proteolytic degradation, optimizes its uptake in local draining lymphatics and reduces its presentation in uninflamed distal lymphoid organs, as shown in mice.

    • Pedro Romero
    • , Alena Donda
    •  & Jeffrey A. Hubbell